Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q2 CY2025 results , with sales up 10.4% year on year to $39.77 million. Its non-GAAP loss of $0.13 per share was 21.5% above ...
Hosted on MSN
PacBio (NASDAQ:PACB) Beats Expectations in Strong Q1
Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q1 CY2025 results , but sales fell by 4.3% year on year to $37.15 million. Its non-GAAP loss of $0.15 per share was 20.5% ...
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism led by a decent first-quarter 2024 ...
Gross margin, operating expenses, net loss, and net loss per share are reported on a GAAP and non-GAAP basis. The non-GAAP measures are described below and reconciled to the corresponding GAAP ...
MENLO PARK, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced its entry into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results